These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 7072727)

  • 61. FDA's dietary sodium initiative--in the war against hypertension, a new weapon.
    Hayes AH
    Public Health Rep; 1983; 98(3):207-10. PubMed ID: 6867251
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of drugs by the medical letter.
    Abramowicz M
    Am J Hosp Pharm; 1976 Jan; 33(1):71-3. PubMed ID: 1266869
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The regulation of dietary supplements in the United States: advocating for a reasonable approach, protecting patient safety, and the role of nursing.
    Vatistas TJ; Samuels JG
    Policy Polit Nurs Pract; 2012 May; 13(2):113-6. PubMed ID: 23044485
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A means to provide patient education: "Rx package inserts, patient package inserts, device labeling".
    Sherman M
    ONA J; 1979 Aug; 6(8):326-9. PubMed ID: 257297
    [No Abstract]   [Full Text] [Related]  

  • 65. An interview with FDA Commissioner Frank Young. Interview by Carmella Bocchino.
    Young FE
    Nurs Econ; 1989; 7(5):242-8. PubMed ID: 2812067
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Statistical efficiencies that the FDA should encourage.
    Overall JE
    Psychopharmacol Bull; 1991; 27(3):211-6. PubMed ID: 1775590
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The PCAST report on pharmaceutical innovation: implications for the FDA.
    Woodcock J
    Clin Pharmacol Ther; 2013 Sep; 94(3):297-300. PubMed ID: 23963215
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dual regulatory pharmaceutical labeling schemes; the role of the Federal Preemption Doctrine.
    Fern FH; Bartell L
    Health Matrix; 1987; 5(3):17-23. PubMed ID: 10285381
    [TBL] [Abstract][Full Text] [Related]  

  • 69. FDA's risk evaluation and mitigation strategies (REMS): effective and efficient safety tools or process poltergeist?
    Wilson A; Milne CP
    Food Drug Law J; 2011; 66(4):569-85, ii. PubMed ID: 24505829
    [TBL] [Abstract][Full Text] [Related]  

  • 70. FDA proposes that patient package insert program be rescinded.
    Hospitals; 1982 Feb; 56(4):84. PubMed ID: 7054117
    [No Abstract]   [Full Text] [Related]  

  • 71. The drug approval process and the FDA.
    Schmidt AM
    Conn Med; 1975 Apr; 39(4):237-40. PubMed ID: 1149447
    [No Abstract]   [Full Text] [Related]  

  • 72. Influence that research and technological developments have had on the ability of the FDA to protect the public health.
    Novitch M
    Ann Ist Super Sanita; 1985; 21(4):459-61. PubMed ID: 3838000
    [No Abstract]   [Full Text] [Related]  

  • 73. Regulatory requirements of the Food and Drug Administration would preclude product claims based on observational research.
    Griffin JP; Godfrey BM; Sherman RE
    Health Aff (Millwood); 2012 Oct; 31(10):2188-92. PubMed ID: 23048095
    [TBL] [Abstract][Full Text] [Related]  

  • 74. History of FDA patient package insert requirements.
    Am J Hosp Pharm; 1980 Dec; 37(12):1660-1. PubMed ID: 7004180
    [No Abstract]   [Full Text] [Related]  

  • 75. FDA's Kessler: a prescription for change. Interview by Marlene Z. Bloom.
    Kessler DA
    Am Pharm; 1991 Dec; NS31(12):34-7. PubMed ID: 1763774
    [No Abstract]   [Full Text] [Related]  

  • 76. The meaning of FDA approval.
    Fischer RG
    Pediatr Nurs; 1987; 13(5):360. PubMed ID: 3658520
    [No Abstract]   [Full Text] [Related]  

  • 77. How does the FDA affect you and your practice?
    Novitch M
    Leg Aspects Med Pract; 1979 Mar; 7(3):23-6. PubMed ID: 423685
    [No Abstract]   [Full Text] [Related]  

  • 78. The public health responsibilities of physicians.
    Goddard JL
    J Am Osteopath Assoc; 1969 Aug; 68(12):240-3. PubMed ID: 5195924
    [No Abstract]   [Full Text] [Related]  

  • 79. [Patient-oriented package inserts for drugs. Historical overview and current status].
    Van Haecht CH; Vander Stichele R; Bogaert M
    Arch Belg; 1989; 47(5-6):230-55. PubMed ID: 2700065
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Some FDA perspectives on data monitoring in clinical trials in drug development.
    O'Neill RT
    Stat Med; 1993 Mar; 12(5-6):601-8; discussion 609-14. PubMed ID: 8493434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.